1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Andros Pharmaceuticals Co.,Ltd

Andros Pharmaceuticals Co.,Ltd

6917.TWO
Andros Pharmaceuticals Co.,LtdTW flagTaipei Exchange
31.30
TWD
-0.20
- -
1.37BMarket Cap
Andros Pharmaceuticals Co.,Ltd
6917.TWO
(Taipei Exchange)

Recent

price

31.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
0.01
0.12
0.48
0.05
0.02
- -
- -
Revenue per Share
-2.12
-1.29
-1.33
-1.21
-1.82
-1.75
- -
Basic EPS, GAAP
-1.98
-1.04
-1.28
-1.05
-1.26
-1.86
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.31
1.12
0.12
1.36
2.08
- -
- -
Book Value per Share
4.64
3.25
2.45
8.21
12.56
8.8
- -
Tangible Book Value per Share
27
28
28
34
38
45
- -
Basic Weighted Avg Shares
- -
3
13
2
1
- -
6
Sales/Revenue/Turnover
-41,159.18
-1,298.68
-262.19
-2,729.77
-9,156.52
-44,142.86
-1,363.3
Operating Margin (%)
9
7
7
6
6
6
7
Depreciation Expense
-58
-36
-37
-41
-68
-78
-54
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-39,418.37
-1,098.13
-278.92
-2,403.74
-8,466.96
-38,561.08
-969.29
Profit Margin (%)
116
80
61
248
421
338
356
Working Capital
39
34
30
26
22
17
12
LT Debt
127
90
69
279
471
394
516
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-76.26
-215.7
-165.99
-109.69
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
73.22%
30.84%
Free Cash Flow
- -
17.68%
-44.34%
Net Income, GAAP
- -
12.69%
-31.3%
Sales/Revenue/Turnover
- -
545.09%
2,633%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
6

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.82
2024
- -
- -
- -
- -
-1.75
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
BeyondSpring Inc. (BYSI)
Aura Biosciences, Inc. (AURA)
PureTech Health plc (PRTC)
Morphic Holding, Inc. (MORF)
TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)
Q BioMed Inc. (QBIO)
Business
Andros Pharmaceuticals Co., Ltd. is a biopharmaceutical enterprise dedicated to advancing innovative drug delivery platform technologies. The firm is progressing APC101, a spray-formulated treatment for post-herpetic neuralgia, which has completed Phase II clinical trials and is now preparing for its Phase III application, with submission for Phase IIb/III clinical trial approval underway in Australia. Additionally, APC201, a foam-based topical anesthetic designed for osteoarthritis discomfort, concluded its Phase II studies, with a comprehensive data report anticipated in the first half of the current year, leading to plans for a global multi-center Phase III study and international licensing initiatives. The company's pipeline further encompasses novel solutions for DNA repair and gene therapy, including oligonucleotide and small interfering RNA (siRNA) candidates, alongside preclinical projects like APC310 and APC501 for various anesthetic applications, and APC401 for post-surgical pain relief. Beyond its developmental assets, Andros offers LALP cream for dermatological analgesic uses, which has achieved market approval and a licensing agreement in Hong Kong, and LTC Cream, a 7% Lidocaine/7% Tetracaine formulation, recognized in Taiwan as a pioneering topical dermatological generic drug under new regulatory standards. Established in 2008, Andros Pharmaceuticals Co., Ltd. operates from its headquarters in Zhubei, Taiwan.